Skip to Content
Merck
CN

SML1898

Iguratimod

≥98% (HPLC)

Synonym(s):

3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one, IGU, N-(7-(Methylsulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide, N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide, T-614

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H14N2O6S
CAS Number:
123663-49-0
Molecular Weight:
374.37
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00882374

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Iguratimod, ≥98% (HPLC)

InChI

1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)

SMILES string

O=S(NC1=CC(OC=C(NC([H])=O)C2=O)=C2C=C1OC3=CC=CC=C3)(C)=O

InChI key

ANMATWQYLIFGOK-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Iguratimod (T-614) is an orally active anti-inflammatory compound that inhibits NF-kappaB (NF-KB) p65 subunit (RelA) phosphorylation and nuclear translocation (30 μg/mL against 10 ng/mL TNF-α; human synovial cells) without affecting IKBα degradation.
Iguratimod (T-614) is an orally active anti-inflammatory compound that inhibits NF-kappaB p65 subunit (RelA) phosphorylation and nuclear translocation.

Storage Class

11 - Combustible Solids

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000496749
0000496749
0000493475
0000493475
027M4723V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Taro Sakamoto et al.
Anticancer research, 36(7), 3301-3306 (2016-06-30)
Angiogenesis is a known factor for the development of hepatocellular carcinoma (HCC). The aim of this study was to assess the property of iguratimod, that is an anti-inflammatory drug for rheumatoid arthritis, on anti-angiogenesis and anti-carcinogensis for HCC. In vitro
Keiichi Tanaka et al.
Expert review of clinical immunology, 11(5), 565-573 (2015-03-24)
Iguratimod (IGU), a small-molecule compound, was developed as a disease-modifying antirheumatic drug in Japan. The pharmacological studies showed that inhibition of the production of cytokines and immunoglobulins mainly contributes to its improvement effect on animal arthritis models. The first clinical
Joshua Bloom et al.
The Journal of biological chemistry, 291(51), 26502-26514 (2016-10-30)
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that has been implicated in a broad range of inflammatory and oncologic diseases. MIF is unique among cytokines in terms of its release profile and inflammatory role, notably as an endogenous

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service